Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Jiaying Pharma to IPO in Shenzhen

publication date: Nov 28, 2007
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Guangdong Jiaying Pharmaceutical has been approved to make its IPO on the Shenzhen stock exchange. The company will issue 20.5 million shares, which will represent 25% of the outstanding shares after the IPO. The five owners of Jiaying have agreed to a 36-month lockup of their personal holdings in the company. Jiaying plans to raise a total of 175 million RMB ($23.6 million) in the offering, implying a price of 8.5 RMB per share. Jiaying will use the money to expand its production facility and build a distribution center. More details...




Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Alibaba IPO
Event Updates
Greg Scott will be attending and speaking at this event:
 
 
Hope to see you there!
 
ChinaBio® Events
 
China Forum 2014

Frankfurt, Germany
November 2, 2014

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors